BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Holdings Lifted by Canada Pension Plan Investment Board

Canada Pension Plan Investment Board grew its position in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) by 20.1% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 474,500 shares of the biotechnology company's stock after purchasing an additional 79,400 shares during the quarter. Canada Pension Plan Investment Board owned approximately 0.25% of BioMarin Pharmaceutical worth $31,189,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Oregon Public Employees Retirement Fund increased its holdings in shares of BioMarin Pharmaceutical by 0.4% in the 4th quarter. Oregon Public Employees Retirement Fund now owns 38,738 shares of the biotechnology company's stock valued at $2,546,000 after acquiring an additional 164 shares during the period. Fifth Third Bancorp boosted its stake in shares of BioMarin Pharmaceutical by 13.9% during the fourth quarter. Fifth Third Bancorp now owns 1,351 shares of the biotechnology company's stock worth $89,000 after buying an additional 165 shares during the period. First Hawaiian Bank grew its holdings in shares of BioMarin Pharmaceutical by 1.4% during the fourth quarter. First Hawaiian Bank now owns 14,700 shares of the biotechnology company's stock worth $966,000 after buying an additional 200 shares during the last quarter. CIBC Private Wealth Group LLC raised its stake in BioMarin Pharmaceutical by 64.2% during the 4th quarter. CIBC Private Wealth Group LLC now owns 596 shares of the biotechnology company's stock valued at $41,000 after acquiring an additional 233 shares during the last quarter. Finally, Blue Trust Inc. raised its stake in BioMarin Pharmaceutical by 27.5% during the 4th quarter. Blue Trust Inc. now owns 1,095 shares of the biotechnology company's stock valued at $77,000 after acquiring an additional 236 shares during the last quarter. Institutional investors and hedge funds own 98.71% of the company's stock.

BioMarin Pharmaceutical Stock Up 0.3 %

Shares of NASDAQ:BMRN traded up $0.20 during mid-day trading on Friday, hitting $62.94. 174,883 shares of the company traded hands, compared to its average volume of 1,890,257. The firm has a market cap of $12.01 billion, a P/E ratio of 28.59, a PEG ratio of 0.61 and a beta of 0.30. BioMarin Pharmaceutical Inc. has a 52-week low of $52.93 and a 52-week high of $94.85. The firm's 50 day simple moving average is $66.44 and its 200 day simple moving average is $66.06. The company has a debt-to-equity ratio of 0.11, a quick ratio of 2.62 and a current ratio of 5.33.

BioMarin Pharmaceutical (NASDAQ:BMRN - Get Free Report) last announced its earnings results on Wednesday, February 19th. The biotechnology company reported $0.72 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.54 by $0.18. The business had revenue of $747.31 million for the quarter, compared to analyst estimates of $711.05 million. BioMarin Pharmaceutical had a return on equity of 9.91% and a net margin of 14.96%. On average, equities analysts anticipate that BioMarin Pharmaceutical Inc. will post 3.15 EPS for the current year.

Insiders Place Their Bets

In related news, CAO Erin Burkhart sold 1,344 shares of the firm's stock in a transaction dated Monday, February 24th. The stock was sold at an average price of $68.38, for a total transaction of $91,902.72. Following the completion of the transaction, the chief accounting officer now owns 13,105 shares of the company's stock, valued at $896,119.90. This trade represents a 9.30 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 0.85% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of equities analysts have commented on BMRN shares. Cantor Fitzgerald restated an "overweight" rating and set a $90.00 price objective on shares of BioMarin Pharmaceutical in a research report on Thursday, February 20th. Bank of America boosted their price objective on shares of BioMarin Pharmaceutical from $99.00 to $103.00 and gave the stock a "buy" rating in a report on Thursday, February 20th. Scotiabank boosted their price target on BioMarin Pharmaceutical from $78.00 to $80.00 and gave the stock a "sector perform" rating in a research note on Thursday, February 20th. UBS Group boosted their target price on BioMarin Pharmaceutical from $109.00 to $113.00 and gave the stock a "buy" rating in a research report on Thursday, February 20th. Finally, Piper Sandler raised their price target on BioMarin Pharmaceutical from $122.00 to $126.00 and gave the company an "overweight" rating in a research report on Thursday, February 20th. Seven investment analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $94.00.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.